- Quotes
- Dashboard
- Chart
- Historical Prices
- Options
- News & PR
- News
- Market Currents
- Press Releases
- Coverage
- Cramer
- Top Analysts
- Business Intelligence
- Transcripts
- Events
- Key Developments
- Earnings
- History & Projected
- Consensus
- Peer Earnings
- Filings
- SEC Filings
- Annual Report
- Financials
- Income Statement
- Balance Sheet
- Cash Flow
52wk high:
52wk low:
EPS:
PE:
Div Rate:
Yield:
Market Cap:
Volume:
BSX Market Currents
more »
-
May 17 Boston Scientific (BSX) +4.1% AH after the FDA approves its Epic vascular stent designed to open blocked arteries in patients with iliac artery stenosis, a form of peripheral vascular disease associated with severe leg pain caused by insufficient blood flow.
Comment![Healthcare, On the Move]
BSX in Focus
more »
BSX Related Articles
more »
BSX News
more »
-
at CNBC.com (May 18, 2012)
-
at CNBC.com (May 17, 2012)
-
at MarketWatch.com (Apr 19, 2012)
-
at MarketWatch.com (Apr 19, 2012)
-
at CNBC.com (Apr 19, 2012)
BSX Press Releases and Filings
more »
-
PR Newswire (May 18, 2012)
-
PR Newswire (May 18, 2012)
-
PR Newswire (May 17, 2012)
-
PR Newswire (May 15, 2012)
-
PR Newswire (May 15, 2012)
BSX Latest Transcript
more »
BSX Cramer
more »
-
Fri, Jul 1, 2011
-
Thu, Sep 16, 2010
-
Tue, Feb 2, 2010
BSX Instablog posts
more »
BSX vs. ETF Alternatives
Company Description
Boston Scientific Corporation is a worldwide developer, manufacturer and marketer of medical devices that are used in a broad range of interventional medical specialties including cardiac rhythm management, electrophysiology, interventional cardiology, peripheral interventions, neurovascular,... More
